We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Depression Tablets 10 and 20 mg
Buprenorphine Opioid dependence 0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films
Eslicarbazepine Epilepsy Tablets 400 and 1200 mg
Fluoxetine Depression Tablets 10 and 20 mg
Lamotrigine Lamotrigine XR tablets 25/ 50/ 100/ 200 & 300 mg
Levetiracetam Epilepsy XR tablets 1; 1,5; 2 and 3 g XR coated minitablets
Pyridostigmine Myasthenia gravis Film-coated tablets 60 mg
Pyridostigminie Myasthenia gravis XR tablets 180 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
Rotigotine Parkinson disease & restless legs Patches 1, 2, 3, 4, 6 and 8 mg/24h
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.